Study details
Enrolling now
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Diakonos Oncology Corporation
NCT IDNCT04157127ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
18
Study length
about 7.4 years
Ages
18+
Locations
3 sites in TX
About this study
This trial is testing a treatment called autologous DC therapy, which uses your own immune cells, in combination with standard chemotherapy for pancreatic cancer. The goal of this phase 1 trial is to determine the safety and feasibility of this new approach.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Autologous DC Therapy
PhasePhase 1
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Overall Survival, Recurrence-Free Survival
Body systems
Oncology